IOL Chemicals & Pharmaceuticals Ltd

- There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. - The company is generating healthy operating cash flows (around Rs. 250 crore for the current year) and plans to fund CAPEX primarily from internal accruals. - CAPEX guidance is around Rs. 150 crore to Rs. 200 crore annually, funded internally. - Future land acquisition and new plant setup for expansion will be funded from internal cash generation. - No discussion or indication of raising external debt or equity was mentioned during the Q&A or closing remarks.

- Current CAPEX for FY24 was Rs. 246 crore, with an average annual CAPEX guidance of Rs. 150-200 crore funded entirely from internal accruals. - Recent CAPEX incurred includes spending on land acquisition near existing Punjab location (~30 km from current site) for future expansion and new plant setups. - Planned CAPEX at this new location is intended to support revenue growth beyond the current Rs. 3,000 crore revenue target by 2028 from existing products. - Growth CAPEX will focus on infrastructure improvements like automation and environmental system installations, expected to positively impact topline and bottom line over the next 2-3 years. - The Rs. 3,000 crore revenue target by 2028 pertains only to existing facilities/products; new CAPEX investments will expand revenue beyond this target. - No specific timelines announced for new product launches like Sitagliptin, with no planned launch in the current financial year.

- Company targets a revenue of Rs. 3,000 crore by FY28 from existing products, implying a CAGR of around 12%-13% per annum. - Revenue growth guidance for FY25 is 10% to 12% for the company overall, including pharma and chemical segments. - Ibuprofen segment expected to grow 10%-12% in FY25. - Non-ibuprofen API segment to grow 40%-45% in FY25. - Specialty chemical segment expected to remain in single-digit growth in FY25, with hopes of recovery later in the year. - Export contribution from non-ibuprofen segment currently around 17%-18%, expected to increase to 25%-40% in FY25. - Volume growth in non-ibuprofen segment increased 10%-15% last year. - Paracetamol capacity is at 95%, with plans to increase capacity to support volume growth. - EBITDA margin target is 14%-15% by FY28, with a PAT margin around 7%-8% in FY25.

- Revenue growth guidance for FY25 is expected at 10% to 12% for the company as a whole, including Pharma and Chemical segments. - EBITDA margin target is set at around 14% to 15% for FY25, improved from 12% in FY24. - PAT margin guidance is around 7% to 8% for FY25, up from approximately 6% in FY24. - For the longer term (up to FY28), topline is projected to grow annually by 12% to 13%, aiming to reach Rs. 3,000 crore from existing products by 2028. - EBITDA margin target for FY28 is around 14% to 15%. - Specialty chemical segment expected to remain in single-digit growth in the near term but with a gradual recovery anticipated. - Export contribution in the non-ibuprofen segment is expected to increase from around 20% to approximately 30%-40% in FY25, supporting revenue growth.

The transcript does not explicitly mention the current or expected order book or pending orders of IOL Chemicals and Pharmaceuticals Limited. However, some relevant points inferred include: - The company is experiencing good queries and business inquiries domestically and for exports in the non-ibuprofen segment, indicating a healthy order inflow. - Exports for Metformin have substantially increased (~60%) compared to last year, suggesting growing demand and likely order buildup. - The company has secured approvals (e.g., ANVISA for Brazil) that enable penetration into new regulated markets, expected to increase future orders. - The Specialty Chemical segment is expected to recover gradually by the end of the year, implying increasing orders in that segment as well. - Overall, while specific order book numbers are not disclosed, growth in exports and approvals hint at a positive order pipeline for FY25 and beyond.